摘要
目的研究2型糖尿病(T2DM)合并心力衰竭(HF)患者应用达格列净治疗后对心功能指标的改善作用。方法选择80例T2DM合并HF患者为研究对象,采用随机数字表法分为观察组与对照组,各40例。对照组患者接受常规HF方案治疗,观察组在对照组基础上联合达格列净治疗。比较两组患者心功能指标[N末端B型脑利钠肽前体(NT-proBNP)]、能量代谢指标[游离脂肪酸(FFA)、β-羟丁酸(β-HB)]、血清因子[同型半胱氨酸(Hcy)、脂联素(ADP)、瘦素(LEP)]、主要不良心血管事件(MACE)及不良反应发生情况。结果治疗前,两组FFA、β-HB、NT-proBNP水平比较均未见显著差异(P>0.05);治疗后,观察组FFA(560.10±10.33)μmol/L及NT-proBNP(2843.07±515.09)pg/ml均低于对照组的(566.45±11.47)μmol/L、(3730.43±520.87)pg/ml,β-HB(0.25±0.03)mmol/L高于对照组的(0.19±0.06)mmol/L(P<0.05)。治疗前,两组ADP、Hcy、LEP水平比较均未见显著差异(P>0.05);治疗后,观察组ADP(20.12±2.14)μg/ml高于对照组的(13.22±2.53)μg/ml,Hcy(10.21±2.32)μmol/L、LEP(8.56±1.56)μg/L均显著低于对照组的(16.33±3.21)μmol/L、(10.81±2.13)μg/L(P<0.05)。观察组MACE及不良反应发生率与对照组比较均未见显著差异(P>0.05)。结论达格列净可有效改善T2DM合并HF患者心功能及能量代谢指标,还可减少MACE发生风险,且具有较高的安全性,对促进患者恢复及预后改善具有重要意义。
Objective To study the effect of dapagliflozin on cardiac function indexes in patients with type 2 diabetes mellitus(T2DM)combined with heart failure(HF).Methods 80 patients with HF combined with T2DM were selected as the study subjects,and were divided into an observation group and a control group using the randomized table method,each with 40 cases.Patients in the control group were treated with conventional HF regimen,and those in the observation group were treated with dapagliflozin on the basis of the control group.Patients in both groups were compared in terms of cardiac function indexes[N-terminal pro-B-type natriuretic peptide(NT-proBNP)],energy metabolism indexes[free fatty acid(FFA),β-hydroxybutyric acid(β-HB)],serum factors[homocysteine(Hcy),adiponectin(ADP),leptin(LEP)],major adverse cardiovascular events(MACE)and the incidence of adverse reactions.Results Before treatment,there were no significant differences in FFA,β-HB and NT-proBNP levels between the two groups(P>0.05).After treatment,the observation group had FFA of(560.10±10.33)μmol/L and NT-proBNP of(2843.07±515.09)pg/ml,which were lower than(566.45±11.47)μmol/L and(3730.43±520.87)pg/ml in the control group;the observation group had a higherβ-HB of(0.25±0.03)mmol/L than(0.19±0.06)mmol/L in the control group(P<0.05).Before treatment,there were no significant differences in ADP,Hcy and LEP levels between the two groups(P>0.05).After treatment,the observation group had a higher ADP of(20.12±2.14)μg/ml than(13.22±2.53)μg/ml in the control group;the observation group had Hcy of(10.21±2.32)μmol/L and LEP of(8.56±1.56)μg/L,which were significantly lower than(16.33±3.21)μmol/L and(10.81±2.13)μg/L in the control group(P<0.05).There were no significant differences in the incidence of MACE and adverse reactions between the observation group and the control group(P>0.05).Conclusion Dapagliflozin can effectively improve cardiac function and energy metabolism indexes in patients with HF combined with T2DM,and also reduce the risk of MACE,and has a high safety profile,which is of great significance in promoting patients'recovery and prognosis.
作者
周雁花
邓刚
王文博
刘红阳
白娟
师园园
韩月霞
王丽
ZHOU Yan-hua;DENG Gang;WANG Wen-bo(Department of Geriatrics,First Affiliated Hospital of Shihezi University,Shihezi 832002,China)
出处
《中国现代药物应用》
2025年第11期98-101,共4页
Chinese Journal of Modern Drug Application
基金
兵团财政科技计划项目(项目编号:2023ZD001)
石河子大学第一附属医院临床研究基金(项目编号:LC202102)。
